SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,726,880, "Electronic Devices for Performing Active Biological Operations and Method of Using Same," by the U.S. Patent and Trademark Office. The '880 patent relates to new devices that enable increased sensitivity of active, programmable electronic matrix (APEX) devices and perform actions such as concentration and assembly of biological materials on a substrate. DNA, RNA, proteins and other biologics can be electronically concentrated at collection electrodes and then re-distributed to reaction or detection electrodes. With alternating manipulation of the collection and reactive electrodes, molecular nanostructures can be assembled for more sensitive detection or used to manufacture molecular structures such as DNA hybrids or Protein/Protein complexes. With the addition of the '880 patent, Nanogen now has 59 issued patents in the United States. "The '880 patent builds upon and extends our previous programmable electronic matrix patents by describing approaches to the collection and concentration of biological materials that can then be manipulated in an organized manner," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Nanogen continues to add to its intellectual property position in order to retain the value of our novel technologies and their potential applications." About Nanogen Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer's disease, and cardiovascular disease. The company's ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen's business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen's website at www.nanogen.com. Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen's NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.